Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Brain & sleep
Dihexa
Dihexa is an experimental angiotensin IV-derived peptide with no human trials and a retracted mechanism paper. See what the research shows and its legal status.
- Reviewed by
- William Maish, MD MBA MPH, Clinical Product Lead
- Published
- April 18, 2026
- Last updated
- October 5, 2026
Key takeaway
Dihexa is an experimental cognition peptide derived from angiotensin IV, sold on the "research peptide" market for brain function. Its evidence is entirely preclinical, with no human trials, and a key paper describing its proposed mechanism has been retracted. As of 2026 it is not FDA-approved or approved anywhere.
What is dihexa?
Dihexa is a synthetic peptide derived from angiotensin IV, designed to be taken orally and cross into the brain. It was developed in academic research as a candidate for cognitive disorders and is sold through "research chemical" channels for brain function and memory. It is not an approved medicine.
How does it work?
Dihexa has been proposed to promote the formation of new connections between nerve cells by enhancing a growth-factor pathway in the brain (hepatocyte growth factor and its receptor, c-Met). An important caveat belongs here: the primary research paper describing this mechanism has since been retracted, which weakens even the preclinical rationale. The remaining supporting data are from cell and rodent experiments. This describes a proposed mechanism, separate from any demonstrated benefit in people.
Is it FDA-approved?
No. Dihexa is not approved by the FDA or by any regulator. It is not on FDA compounding lists and was not among the peptides reviewed at the 2026 FDA compounding advisory meetings.
What does the research show?
The evidence is preclinical, and partly compromised. Animal experiments (such as maze-based memory tests1) have been reported, but the foundational mechanism paper has been retracted2, and there are no completed human efficacy trials. There is no sound human evidence that dihexa improves cognition.
Sources: general reference literature on therapeutic peptides noting the absence of clinical trials for dihexa (Journal of the AAOS Global Research & Reviews, 2025, DOI: 10.5435/JAAOSGlobal-D-25-002363), indexed on PubMed; the retraction of the primary dihexa mechanism paper is noted in the PubMed record. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.